Stay updated on Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial
Sign up to get notified when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.

Latest updates to the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check66 days agoChange DetectedThe webpage has been updated to include new drug names, Regorafenib and Cabozantinib, in the context of a clinical trial for Hepatocellular Carcinoma (HCC), while significant background information about HCC and its relation to HBV has been removed.SummaryDifference47%
- Check73 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 24, 2025.SummaryDifference0.2%
Stay in the know with updates to Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.